Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

We recommend the following alternatives

W         ChIP M
REACTIVITY SENSITIVITY MW (kDa) SOURCE
280 Rabbit

Product Usage Information

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

TET2 Antibody (Mouse Specific) recognizes endogenous levels of total mouse TET2 protein.


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val1640 of mouse TET2 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Methylation of DNA at cytosine residues is a heritable, epigenetic modification that is critical for proper regulation of gene expression, genomic imprinting, and mammalian development (1,2). 5-methylcytosine is a repressive epigenetic mark established de novo by two enzymes, DNMT3a and DNMT3b, and is maintained by DNMT1 (3, 4). 5-methylcytosine was originally thought to be passively depleted during DNA replication. However, subsequent studies have shown that Ten-Eleven Translocation (TET) proteins TET1, TET2, and TET3 can catalyze the oxidation of methylated cytosine to 5-hydroxymethylcytosine (5-hmC) (5). Additionally, TET proteins can further oxidize 5-hmC to form 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), both of which are excised by thymine-DNA glycosylase (TDG), effectively linking cytosine oxidation to the base excision repair pathway and supporting active cytosine demethylation (6,7). TET2 is the most frequently mutated gene in myeloid dysplastic syndrome (MDS), a dysplasia of myeloid, megakaryocytic, and/or erythroid cell lineages, of which 30% progress to acute myeloid leukemia (AML) (8, 9). It is also mutated in diffuse large B-cell lymphoma (10). TET2 protein expression is often reduced in solid tumors such as prostate cancer, melanoma, and oral squamous cell carcinoma (11-13).


1.  Hermann, A. et al. (2004) Cell Mol Life Sci 61, 2571-87.

2.  Turek-Plewa, J. and Jagodziński, P.P. (2005) Cell Mol Biol Lett 10, 631-47.

3.  Okano, M. et al. (1999) Cell 99, 247-57.

4.  Li, E. et al. (1992) Cell 69, 915-26.

5.  Tahiliani, M. et al. (2009) Science 324, 930-5.

6.  He, Y.F. et al. (2011) Science 333, 1303-7.

7.  Ito, S. et al. (2011) Science 333, 1300-3.

8.  Langemeijer, S.M. et al. (2009) Nat Genet 41, 838-42.

9.  Yamazaki, J. et al. (2012) Epigenetics 7, 201-7.

10.  Asmar, F. et al. (2013) Haematologica 98, 1912-20.

11.  Nickerson, M.L. et al. (2013) Hum Mutat 34, 1231-41.

12.  Lian, C.G. et al. (2012) Cell 150, 1135-46.

13.  Jäwert, F. et al. (2013) Anticancer Res 33, 4325-8.


Entrez-Gene Id 214133
Swiss-Prot Acc. Q4JK59


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
Tween is a registered trademark of ICI Americas, Inc.

70153
TET2 Antibody (Mouse Specific)